Halberd News

Press releases and updates on our medical breakthroughs.

Oct 20 2021

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

By |2021-10-19T21:30:49-04:00October 20th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity.  Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...

Oct 19 2021

Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

By |2021-10-19T20:51:31-04:00October 19th, 2021|Press Releases|Comments Off on Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance

Abstract Aims/hypothesis A subset of obese individuals remains insulin sensitive by mechanisms as yet unclear. The hypothesis that maintenance of normal subcutaneous (SC) adipogenesis accounts, at least partially, for this protective phenotype and whether it can be abrogated by chronic exposure to IL-6 was investigated. Methods Adipose tissue biopsies were collected from insulin-sensitive (IS) and ...

Oct 19 2021

Insulin Resistance Associated To Obesity: The Link TNF-Alpha

By |2021-10-19T20:43:06-04:00October 19th, 2021|Press Releases|Comments Off on Insulin Resistance Associated To Obesity: The Link TNF-Alpha

Iria Nieto-Vazquez, Sonia Fernández-Veledo, David K. Krämer,Rocio Vila-Bedmar, Lucia Garcia-Guerra & Margarita Lorenzo Abstract Adipose tissue secretes proteins which may influence insulin sensitivity. Among them, tumour necrosis factor (TNF)-alpha has been proposed as a link between obesity and insulin resistance because TNF-alpha is overexpressed in adipose tissue from obese animals and humans, and obese mice ...

Oct 19 2021

Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

By |2021-10-19T20:34:25-04:00October 19th, 2021|Press Releases|Comments Off on Fat-fighting Nanoparticles New Drug-Delivery Approach Holds Potential For Treating Obesity

SOURCE: https://news.mit.edu/2016/fat-fighting-nanoparticles-obesity-0502   "Researchers at MIT and Brigham and Women’s Hospital have developed nanoparticles that can deliver antiobesity drugs directly to fat tissue. Overweight mice treated with these nanoparticles lost 10 percent of their body weight over 25 days, without showing any negative side effects. The drugs work by transforming white adipose tissue, which is ...

Oct 19 2021

Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

By |2021-10-19T20:31:40-04:00October 19th, 2021|Press Releases|Comments Off on Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico

Abstract Objective: We undertook this study to determine the relationship among -174G>C and 598G>A polymorphisms in the promoter region of interleukin-6, obesity, and metabolic abnormalities in subjects from central Mexico. Methods: Included in the study were 150 subjects who were not first-degree relatives of patients with diabetes and 106 blood samples from the general population. ...

Oct 19 2021

Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

By |2021-10-19T20:41:18-04:00October 19th, 2021|Press Releases|Comments Off on Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans

Abstract Objective: To investigate the relationship between alpha 1-antitrypsin (A1AT), adiponectin, leptin, blood glucose, and insulin protein levels in human serum and obesity. Methods: Forty-eight subjects with normal blood glucose levels and average age of 32.4+/-5.1 years were enrolled in this study. The study took place in the Reproductive Center, The Second Hospital of Jilin University, Changchun, ...

Oct 12 2021

Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement

By |2021-10-11T21:52:59-04:00October 12th, 2021|Featured, Investor News, News|0 Comments

GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer’s Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd’s VitaShieldMaxTM Immune Support through their online ecommerce platform. Jackson Center, PA, October 12, 2021 – Halberd Corporation (OTC-PINK: HALB) and GTX Corp (OTC-PINK: GTXO) have agreed to work together on various ...

Oct 7 2021

Halberd Corporation CEO Letter

By |2021-10-04T21:24:09-04:00October 7th, 2021|Featured, Investor News, News|0 Comments

Q3-21 Accomplishments and Q4 Plans Jackson Center, PA, October 7, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer’s Disease, Parkinson’s Disease, etc. As ...

Oct 5 2021

Halberd’s VITASHIELDMAX(TM) Immunity Support Product Available on Amazon

By |2021-10-04T20:45:12-04:00October 5th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, October 5, 2021 – Halberd Corporation (OTC-PINK: "HALB") announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in addition to its availability through Halberd’s website at www.vitashieldmax.com. William A. Hartman, Halberd's Chairman, President & CEO, stated, “We are pleased that our product will now also be available through ...

Sep 22 2021

Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement

By |2021-09-21T19:05:47-04:00September 22nd, 2021|Featured, Investor News, News|0 Comments

Agreement To Advance Healthcare Diagnostic Technologies Jackson Center, PA, September 22, 2021 – Halberd Corp. (OTC PINK: HALB) and heliosDx, a wholly owned company of Rush Net, Inc.(OTC PINK: RUSH), an Alpharetta, GA company, announce a Scientific Collaboration Agreement to explore synergies and opportunities mutually beneficial to both companies.  A major objective of the agreement ...

Go to Top